- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Reports Increased Profitability in Q1
Accelrys, Inc. (NASDAQ:ACCL) today reported financial results for the quarter ended June 30, 2007.
"We are pleased with our financial performance in the first quarter of fiscal year 2008," said Mark J. Emkjer, Accelrys President and Chief Executive Officer. “We continue to demonstrate profitability and earnings growth despite challenging market conditions and budget constraints experienced by our large pharmaceutical customers in early stage discovery. In the first quarter we experienced solid growth from our scientific operating platform which was offset by some continued erosion in our legacy products. We expect that the upcoming second quarter release of Discovery Studio 2.0 and Materials Studio 4.2 will begin to stabilize our legacy revenue stream in the ensuing quarters ahead. We continue to believe that our scientific operating platform provides us with significant growth opportunities into the scientific business intelligence marketplace and we will be accelerating our investment in this area to drive future revenue growth.”
Revenue for the quarter ended June 30, 2007 was $20.1 million, compared to revenue of $20.2 million for the same quarter of the previous year. Revenue in the current quarter was favorably impacted by continued growth in the Company’s scientific operating platform product line, offset by reduced revenues in the legacy modeling and simulation products.
Non-GAAP operating income was $2.1 million for the current quarter, a 46% increase over non-GAAP operating income of $1.5 million for the same quarter of the previous year. On a GAAP basis, operating income for the current quarter was $0.8 million, compared to a $0.4 million operating loss for the same quarter of the previous year. Operating income on both a GAAP and non-GAAP basis was favorably impacted in the current quarter by savings realized in connection with the closure of our Bangalore research and development facility in the fourth quarter of fiscal year 2007 and other cost control measures implemented in previous periods, partially offset by increased personnel related costs associated with our expanded sales and sales support organization. Operating income on a GAAP basis was also favorably impacted by the elimination of restatement-related costs that were incurred in the prior year.
Non-GAAP net income was $2.7 million, or $0.10 per diluted share, for the current quarter, a 75% increase from non-GAAP net income of $1.6 million, or $0.06 per diluted share, for the same quarter of the previous year. On a GAAP basis, the Company reported net income of $1.4 million, or $0.05 per diluted share, for the current quarter, compared to a net loss of $0.3 million, or $0.01 per diluted share, for the same quarter of the previous year. Net income on both a GAAP and non-GAAP basis was favorably impacted in the current quarter by the savings realized in operating income noted above, in addition to favorable fluctuations in foreign currencies and higher interest rates obtained on our cash and marketable securities balances during the current quarter.
At June 30, 2007, the Company had total cash, cash equivalents, restricted cash and marketable securities of $68.7 million, an increase of $5.4 million from the year ago quarter.
Financial, Business and Product Development Highlights:
Non-GAAP Financial Measures:
This press release describes financial measures for operating income, net income, and net income per share that exclude stock-based compensation expense, amortization of purchased intangible assets, restructuring charges and costs incurred to complete the Company’s restatement. These financial measures are not calculated in accordance with generally accepted accounting principles (GAAP) and are not based on any comprehensive set of accounting rules or principles.
Management believes these non-GAAP financial measures provide a useful measure of the Company’s operating results, a meaningful comparison with historical results and with the results of other companies, and insight into the Company’s on-going operating performance. Further, management and the Board of Directors utilize these measures, in addition to GAAP measures, when evaluating and comparing the Company’s operating performance against internal financial forecasts and budgets. These non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. In addition, these non-GAAP financial measures may be different from non-GAAP financial measures used by other companies.
For additional information on the items excluded by the Company from its non-GAAP financial measures please refer to the Form 8-K regarding this release that was furnished today with the Securities and Exchange Commission.
The following table contains a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures (unaudited, amounts in thousands, including footnotes):
Three Months Ended
|GAAP Operating income (loss)||$||830||$||(416||)|
Stock-based compensation expense1
Purchased intangible asset amortization2
|Non-GAAP Operating income||$||2,139||$||1,470|
|GAAP Net income (loss)||$||1,419||$||(329||)|
|Stock-based compensation expense||903||1,009|
|Purchased intangible asset amortization||381||384|
|Non-GAAP Net income||$||2,728||$||1,557|
|GAAP Diluted net income (loss) per share||$||0.05||$||(0.01||)|
|Stock-based compensation expense||0.03||0.04|
|Purchased intangible asset amortization||0.01||0.01|
Non-GAAP Diluted net income per share4
1 Stock-based compensation expense is included in our consolidated statement of operations as follows:
Three Months Ended
|Cost of revenue||$||81||$||71|
|Sales and marketing||201||159|
|General and administrative||391||434|
|Total stock-based compensation expense||$||903||$||1,009|
2 Purchased intangible asset amortization is included in the cost of revenue line in our consolidated statement of operations.
3 Restructuring charges and restatement-related costs are included in the general and administrative expenses line in our consolidated statement of operations.
4 Earnings per share amounts for the three months ended June 30, 2007 do not add due to rounding.
Conference Call Details:
At 5:00 p.m. ET today, Accelrys will conduct a conference call to discuss its financial results. To participate, please dial (800) 573-4752 (+(617) 224-4324 outside the United States) and enter the access code, 31790151, approximately 15 minutes before the scheduled start of the call. The conference call will also be accessible live on the Investor Relations section of the Accelrys website at www.accelrys.com.
A replay of the conference call will be available online at www.accelrys.com and via telephone by dialing (888) 286-8010 (+1 (617) 801-6888 outside the United States) and entering access code, 66976038, beginning 7:00 p.m. ET on August 1, 2007 through 5:00 p.m. ET on November 1, 2007.
About Accelrys, Inc.
Accelrys develops and commercializes scientific business intelligence software for the integration, mining, analysis, modeling and simulation, management and interactive reporting of scientific data. Our solutions are used by biologists, chemists, materials scientists, and information technology professionals for product design and drug discovery and development. Our technology and services are designed to meet the needs of today’s leading research and development organizations including leading commercial, government and academic organizations. Many of the largest pharmaceutical, biotechnology, chemical, and petroleum companies worldwide use our solutions. Accelrys is headquartered in San Diego, California. For more information about Accelrys, visit its website at http://www.accelrys.com/ .
Statements contained in this press release relating to the Company's or management's intentions, hopes, beliefs, expectations or predictions of the future are forward-looking statements. Such forward-looking statements including, but not limited to, statements relating to the future releases of the Company’s products, the stabilization of the Company’s legacy revenue stream, the long-term growth of the Company, and acceleration of the Company’s investment in its scientific business intelligence product platform, are subject to a number of risks and uncertainties. These include risks that the Company will not achieve its anticipated results or long-term growth plans, that the Company’s competitive position will not improve, and/or that such growth will not occur due to, among other possibilities, a lack of demand for or market acceptance of the Company’s products, as well as the risks and uncertainties that are contained from time to time in the Company's SEC filings, including, but not limited to, the Company's Annual Report on Form 10-K for the year ended March 31, 2007, quarterly reports on Form 10-Q and current reports on Form 8-K. The Company's actual results could differ materially from those projected in such forward-looking statements due to these risks and uncertainties, and the Company disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future events or otherwise.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
Three Months Ended
|Cost of revenue||3,507||3,656|
|Sales and marketing||7,540||7,066|
|General and administrative||3,915||4,718|
|Total operating expenses||15,764||16,910|
|Operating income (loss)||830||(416||)|
|Interest and other income, net||992||484|
|Income before taxes||1,822||68|
|Income tax expense||403||397|
|Net income (loss)||$||1,419||$||(329||)|
|Basic and diluted net income (loss) per share||$||0.05||$||(0.01||)|
|Weighted average shares used to compute net income (loss) per share|
CONDENSED CONSOLIDATED BALANCE SHEETS
|June 30, 2007||March 31, 2007|
|Cash, cash equivalents, marketable securities and restricted cash and marketable securities||$||68,662||$||70,757|
|Trade receivables, net||10,074||18,617|
|Other assets, net||59,939||65,227|
|Liabilities and stockholders’ equity|
|Current liabilities, excluding deferred revenue||10,789||21,136|
|Total deferred revenue||47,140||56,133|
|Noncurrent liabilities, excluding deferred revenue||8,457||8,342|
|Total stockholders’ equity||72,289||68,990|
|Total liabilities and stockholders’ equity||$||138,675||$||154,601|
For more information, please click here
Rick Russo, 858-799-5200
Charles Messman or Todd Kehrli, 323-468-2300
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Discovery of the specific properties of graphite-based carbon materials February 6th, 2016
Study reveals how herpes virus tricks the immune system February 5th, 2016
Hepatitis virus-like particles as potential cancer treatment February 5th, 2016
Arrowhead to Webcast Fiscal 2015 Year End Results December 7th, 2015
Haydale Announce Year End Results November 3rd, 2015
Small but heading for the big time: Nanobiotix half year results for the six months ended 30 June 2015, in line with expectations: Major clinical achievements and corporate developments August 28th, 2015